

comments on or objections to the issuance of the proposed registration on or before August 1, 2019. Such persons may also file a written request for a hearing on the application on or before August 1, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia

22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register

Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:**

In accordance with 21 CFR 1301.34(a), this is notice that on February 18, 2019, Sigma Aldrich Co., LLC, 3500 DeKalb Street, Saint Louis, Missouri 63118 applied to be registered as an importer of the following basic classes of controlled substances:

| Controlled substance                    | Drug code | Schedule |
|---|-----------|----------|
| Cathinone                               | 1235      | I        |
| Methcathinone                           | 1237      | I        |
| Mephedrone (4-Methyl-N-methylcathinone) | 1248      | I        |
| Aminorex                                | 1585      | I        |
| Gamma Hydroxybutyric Acid               | 2010      | I        |
| Methaqualone                            | 2565      | I        |
| Alpha-ethyltryptamine                   | 7249      | I        |
| Ibogaine                                | 7260      | I        |
| Lysergic acid diethylamide              | 7315      | I        |
| Marihuana                               | 7360      | I        |
| Tetrahydrocannabinols                   | 7370      | I        |
| Mescaline                               | 7381      | I        |
| 4-Bromo-2,5-dimethoxyamphetamine        | 7391      | I        |
| 4-Bromo-2,5-dimethoxyphenethylamine     | 7392      | I        |
| 4-Methyl-2,5-dimethoxyamphetamine       | 7395      | I        |
| 2,5-Dimethoxyamphetamine                | 7396      | I        |
| 3,4-Methylenedioxyamphetamine           | 7400      | I        |
| N-Hydroxy-3,4-methylenedioxyamphetamine | 7402      | I        |
| 3,4-Methylenedioxy-N-ethylamphetamine   | 7404      | I        |
| 3,4-Methylenedioxymethamphetamine       | 7405      | I        |
| 4-Methoxyamphetamine                    | 7411      | I        |
| Bufotenine                              | 7433      | I        |
| Diethyltryptamine                       | 7434      | I        |
| Dimethyltryptamine                      | 7435      | I        |
| Psilocyn                                | 7438      | I        |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine   | 7470      | I        |
| N-Benzylpiperazine                      | 7493      | I        |
| MDPV (3,4-Methylenedioxypropylvalerone) | 7535      | I        |
| Heroin                                  | 9200      | I        |
| Normorphine                             | 9313      | I        |
| Etonitazene                             | 9624      | I        |
| Amobarbital                             | 2125      | II       |
| Secobarbital                            | 2315      | II       |
| Glutethimide                            | 2550      | II       |
| Nabilone                                | 7379      | II       |
| Phencyclidine                           | 7471      | II       |
| Diphenoxylate                           | 9170      | II       |
| Ecgonine                                | 9180      | II       |
| Ethylmorphine                           | 9190      | II       |
| Levorphanol                             | 9220      | II       |
| Meperidine                              | 9230      | II       |
| Thebaine                                | 9333      | II       |
| Opium, powdered                         | 9639      | II       |
| Levo-alphaacetylmethadol                | 9648      | II       |

The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis. In reference to drug codes 7360 and 7370 the company plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. No other activities for these drug codes are authorized for this registration.

Dated: June 18, 2019.  
**John J. Martin,**  
*Assistant Administrator.*  
 [FR Doc. 2019-14025 Filed 7-1-19; 8:45 am]  
**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**  
**Drug Enforcement Administration**  
**[Docket No. DEA-392]**  
**Importer of Controlled Substances**  
**Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and been granted registration by the Drug Enforcement

Administration (DEA) as importer of schedule I controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as an importer of basic class of controlled substances. Information on previously published notice is listed in the table below. No comments or objections were submitted and no requests for a hearing were submitted for this notice.

| Company                 | FR Docket   | Published      |
|-------------------------|-------------|----------------|
| Sharp (Bethlehem), LLC. | 84 FR 9837. | March 18, 2019 |

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic class of schedule I controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I controlled substances to the above listed company.

Dated: June 3, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-14023 Filed 7-1-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Application: Bellwyck Clinical Services**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 1, 2019. Such persons may also file a written request for a hearing on the application on or before August 1, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement

Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on April 17, 2019, Bellwyck Clinical Services, 8946 Global Way, West Chester, Ohio 45069 applied to be registered as an importer of the following basic class of controlled substances:

| Controlled substance | Drug code | Schedule |
|----------------------|-----------|----------|
| Amphetamine ...      | 1100      | II       |
| Methylphenidate ...  | 1724      | II       |
| Oxycodone .....      | 9143      | II       |

The company plans to import the listed controlled substances in dosage form to conduct clinical trials. Approval of permit applications will occur only when the registrant's activity is consistent with what is authorized under 21 U.S.C. 952(a) (2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: June 18, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-14027 Filed 7-1-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Application: Pisgah Laboratories, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 3, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement

Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March 5, 2019, Pisgah Laboratories, Inc., 3222 Old Hendersonville Highway, Pisgah Forest, North Carolina 28768 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Controlled substance       | Drug code | Schedule |
|----------------------------|-----------|----------|
| Difenoxin .....            | 9168      | I        |
| Diphenoxylate ...          | 9170      | II       |
| Levorphanol .....          | 9220      | II       |
| Meperidine intermediate-B. | 9233      | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Dated: June 19, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-14028 Filed 7-1-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Application: Lipomed**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 1, 2019. Such persons may also file a written request for a hearing on the application on or before August 1, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register